

Information derived from such an update, when compared with the earlier data base, should afford a basis for determining trends.

Lilly also has under consideration the possibility of a prospective study of medical examiner and emergency room cases to develop in-depth and accurate information on the circumstances of drug misuse in accidental and intentional overdose situations.

In testimony during the recent Senate hearings several suggestions for additional studies were made, and the company has these suggestions under consideration.

Conclusion

In summary, Lilly believes that propoxyphene is a safe and effective analgesic when used as directed. The company does not believe that death or serious injury has resulted from the proper use of propoxyphene products. All reliable data indicate that propoxyphene-related deaths are associated with improper use.

Data both from the DAWN system and from independent reports by toxicologists indicate that propoxyphene-associated deaths, which reached a peak in late 1976 and early 1977,